The paper provides a brief summary of current preclinical and clinical evidences of dopaminergic system involvement in OCD pathophysiology. We also provide an overview of effectiveness and long-term safety of dopaminergic agents in the treatment of resistant OCD.
Keywords: OCD, resistant-OCD, antipsychotics augmentation, dopamine agents, ondansetron, endogenous, placebo-controlled, quetiapine, olanzapine, aripiprazole, Haloperidol, risperidone augmentation, Sydenham's chorea, amphetamine, cocaine
promotion: free to download
Rights & PermissionsPrintExport